Theralink Technologies Inc - THER STOCK NEWS

Theralink Technologies, Inc. (OTC: THER) and IMAC Holdings, INC (Nasdaq: BACK) have responded to the SEC’s first round of comments on the jointly filed form S-4, a registration statement required for a merger or acquisition. This signifies a major milestone as it moves the transaction forward, creating a well-positioned proteomics pure play focused on the next generation of cancer care and protein analysis.

Theralink Technologies announces promising results from its partnership with Inova Schar Cancer Institute to integrate Theralink's RPPA technology into Inova's Molecular Tumor Board. The partnership aims to improve treatment selection and patient-tailored therapy regimes by combining genomic and proteomic analysis. Interim results showed a clinical recommendation change for over half of the patients and additional treatment considerations for 59% of the patients. Theralink's proteomics data also revealed a mechanism of resistance for a targeted therapy. Another study highlighted Theralink's ability to measure HER2 abundance in pancreatic tumors. Final study analysis and results are expected in early 2024.

Theralink Technologies announces filing of Form S-4 for merger with IMAC Holdings, creating a new NASDAQ-listed company focused on proteomics testing.

Theralink Technologies (OTC: THER) has expanded its patent portfolio to 10 by acquiring an exclusive license for U.S. patent US 10,969,392 from Vanderbilt University. This patent relates to methods for predicting patient responses to immunotherapies, enhancing Theralink's capabilities in precision oncology. The incorporation of predictive biomarkers will aid in identifying patients who are most likely to benefit from specific therapeutic approaches, particularly in breast cancer and other solid tumors. This strategic acquisition positions Theralink to improve clinical outcomes through advanced companion diagnostics and personalized treatment options.

Theralink Technologies (OTC: THER) announced on Feb. 23, 2023, that it has begun receiving payments from third-party payors for its advanced breast cancer assay. This milestone highlights the company's innovative phosphoprotein-based testing technology, which aims to provide oncologists with actionable information to enhance treatment decisions. CEO Mick Ruxin emphasized that this achievement reflects the company's growth and commitment to improving cancer care access across the U.S. Theralink's patented technology measures tumor cell levels of activated proteins, which are critical for FDA-approved therapies and investigational drugs.

Theralink Technologies (OTC: THER) announced its support for George Mason University’s role in the White House Cancer Moonshot Initiative. The company's RPPA technology, acquired through an exclusive license, aims to enhance cancer care and improve drug efficacy identification. CEO Mick Ruxin emphasized the importance of collaboration in reducing cancer mortality rates. Emanuel Petricoin, co-director of the Center for Applied Proteomics and Molecular Medicine, expressed optimism about halving cancer death rates in 25 years. Theralink, based in Golden, Colorado, focuses on precision oncology through its novel assays for various cancers.

Theralink Technologies (OTC: THER) has appointed Michael Vallone as Senior Director of Commercialization, signaling a shift towards a commercially driven enterprise. Vallone brings extensive experience in commercialization and oncology, having spent 15 years with a leading genetics company. His appointment aims to enhance Theralink's commercialization strategy for its unique RPPA technology, which is the only U.S. assay capable of predicting effective FDA-approved drugs for cancer treatment. Theralink's goal is to improve patient care while achieving profitability.

Theralink Technologies has appointed Faith Zaslavsky as President and Chief Operating Officer, effective December 5, 2022. Zaslavsky, a seasoned leader in genomics and oncology, brings extensive experience from her role as President of Oncology at a $150 million division within a life sciences company. Theralink, known for its patented RPPA technology, aims to improve precision oncology through its assays and has recently achieved final price determination for Medicare reimbursement, enhancing market access for its testing services.